GELS (Gelteq) Interest Received: $0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GELS Gelteq Ltd GELS
8 GF Score
Price $0.53
! 5 Warning Signs
View Full Analysis

What is Gelteq Interest Received?

Gelteq GELS +3.09% 8 Interest Received is $0.00 Mil as of Dec. 2025. GuruFocus rates GELS with a GF Score™ of 8/100. The stock has 5 warning signs investors should review.

Gelteq's Interest Received for the six months ended in Dec. 2025 was $0.00 Mil.

Gelteq's Interest Received for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

Gelteq Interest Received Related Terms

Gelteq Interest Received Historical Data

* Premium members only.

The historical data trend for Gelteq's Interest Received can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gelteq Interest Received Chart

Gelteq Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Interest Received
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Gelteq Semi-Annual Data
Jun20 Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Received Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
GELS
8GF Score
Gelteq Ltd GELS
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gelteq Interest Received Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Interest Received represents interest received by the company in the direct cash flow method.

Interest Received for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Received →
What does a Interest Received of $0.00 Mil mean?
Gelteq (GELS) has a Interest Received of $0.00 Mil as of Dec. 2025. Interest Received represents interest received by the company in direct cash flow method. View historical data for Gelteq and its competitors.
Is Gelteq's Interest Received too high?
Gelteq's current Interest Received is $0.00 Mil. Overall, Gelteq has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Gelteq's Interest Received compare to YCBD and AKAN?
Gelteq's Interest Received of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Received for a Drug Manufacturers company?
A good Interest Received depends on the Drug Manufacturers industry context. However, Interest Received should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Received mean?
A high Interest Received can signal that a stock is expensive relative to its fundamentals. Interest Received represents interest received by the company in direct cash flow method. View historical data for Gelteq and its competitors. Gelteq's current Interest Received is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelteq stock overvalued right now?
Gelteq (GELS) has a current Interest Received of $0.00 Mil. The current Interest Received is $0.00 Mil. Gelteq's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Received calculated?
Interest Received is calculated from a company's financial statements. For Gelteq (GELS), the current Interest Received is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gelteq Business Description

Address 644 Chapel Street, Level 19, South Yarra, VIC, AUS, 3141
Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.
8GF Score

Get the complete analysis for GELS

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.53
Price